Clinical Trials Directory

Trials / Conditions / Metastatic Bladder Urothelial Carcinoma

Metastatic Bladder Urothelial Carcinoma

17 registered clinical trials studyying Metastatic Bladder Urothelial Carcinoma — 4 currently recruiting.

StatusTrialSponsorPhase
RecruitingTherapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
NCT07087860
Mayo ClinicPhase 2
RecruitingEnfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bl
NCT06764095
Mayo ClinicPhase 4
RecruitingPemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metasta
NCT06630416
Northwestern UniversityPhase 2
RecruitingImmune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
NCT06349642
Mayo Clinic—
Active Not RecruitingTesting Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemo
NCT04963153
National Cancer Institute (NCI)Phase 1
Active Not RecruitingTesting the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in
NCT05092958
National Cancer Institute (NCI)Phase 3
Active Not RecruitingTrying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
NCT04637594
Alliance for Clinical Trials in OncologyPhase 3
Active Not RecruitingTocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or
NCT04940299
M.D. Anderson Cancer CenterPhase 2
Active Not RecruitingARID1A and/or KDM6A Mutation and CXCL13 Expression
NCT04953104
M.D. Anderson Cancer CenterPhase 2
Active Not RecruitingComparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastat
NCT04579224
National Cancer Institute (NCI)Phase 3
Active Not RecruitingImmune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
NCT04848519
Emory UniversityPhase 2
WithdrawnAdoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable o
NCT03935347
Roswell Park Cancer InstitutePhase 2
CompletedAtezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial C
NCT03513952
National Cancer Institute (NCI)Phase 2
Active Not RecruitingPembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small
NCT03582475
Jonsson Comprehensive Cancer CenterPhase 1
Active Not RecruitingAtezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metasta
NCT03237780
National Cancer Institute (NCI)Phase 2
CompletedCisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Uroth
NCT02567409
National Cancer Institute (NCI)Phase 2
CompletedGemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary
NCT00942331
National Cancer Institute (NCI)Phase 3